Background The landscape of inflammatory bowel disease (IBD) treatment is rapidly
expanding with the development of new therapeutic options. Aim To review the mechanisms …

Background & Aims Guselkumab, a selective p19 interleukin-23 antagonist, is approved for
the treatment of plaque psoriasis and psoriatic arthritis. This study evaluated the efficacy and …

Background & Aims Fecal microbiota transplantation (FMT) is an emerging treatment
modality for ulcerative colitis (UC). Several randomized controlled trials have shown efficacy …

Inflammatory bowel disease (IBD) is a chronic relapsing-remitting inflammatory disease of
the gastrointestinal tract. Patients are usually diagnosed in adolescence and early …

Abstract Coronavirus disease 2019 (COVID-19), represents an enormous new threat to our
healthcare system and particularly to the health of older adults. Although the respiratory …

Abstract Treatment strategies for inflammatory bowel disease (IBD) are rapidly evolving with
the development of biologics and small molecule drugs (SMDs). However, these drugs are …

In the beginning of the third year of the fight against COVID-19, the virus remains at least still
one step ahead in the pandemic “war”. The key reasons are evolving lineages and …

Background Currently, inflammatory bowel disease (IBD) has become a global chronic
idiopathic disease with ever-rising morbidity and prevalence. Accumulating evidence …

Inflammatory bowel disease is a group of conditions of unknown etiology, represented by
Crohn's disease and ulcerative colitis and characterized by the presence of intestinal wall …

Abstract Background Qingchang Wenzhong Decoction (QCWZD), a chinese herbal
prescription, is widely used for ulcerative colitis (UC). Nevertheless, the active ingredients …